Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHXJ68)

Drug Name

WVE-210201 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Duchenne dystrophy	8C70	Phase 2/3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dystrophin (DMD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fordadistrogene movaparvovec	DMZ3X7F	Duchenne muscular dystrophy	8C70.1	Phase 3	[3]
SRP-9001	DMR09IH	Duchenne dystrophy	8C70	Phase 2	[4]
MyoDys	DMHO6XP	Duchenne dystrophy	8C70	Phase 1	[5]
Biostrophin	DMS4P6K	Duchenne dystrophy	8C70	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03907072) Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT05689164) Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study. U.S.National Institutes of Health.
4	Clinical pipeline report, company report or official report of Sarepta Therapeutics.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009280)
6	Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013 Jun;14(6):373-8.